Iradimed Corporation (NASDAQ:IRMD) CFO John Glenn Sells 2,500 Shares

Iradimed Corporation (NASDAQ:IRMD) CFO John Glenn sold 2,500 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $54.18, for a total transaction of $135,450.00. Following the sale, the chief financial officer now owns 4,383 shares in the company, valued at $237,470.94. This represents a 36.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Iradimed Stock Down 0.2 %

IRMD traded down $0.09 on Monday, hitting $53.84. The company had a trading volume of 29,204 shares, compared to its average volume of 48,532. Iradimed Corporation has a 12-month low of $40.18 and a 12-month high of $57.95. The business’s fifty day simple moving average is $51.69 and its 200 day simple moving average is $47.27. The company has a market cap of $682.09 million, a PE ratio of 36.87 and a beta of 0.79.

Iradimed Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, November 25th. Stockholders of record on Friday, November 15th were given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 1.11%. The ex-dividend date of this dividend was Friday, November 15th. Iradimed’s dividend payout ratio is currently 41.10%.

Institutional Trading of Iradimed

A number of institutional investors have recently bought and sold shares of IRMD. 1620 Investment Advisors Inc. purchased a new position in shares of Iradimed during the 2nd quarter worth about $25,000. Comerica Bank lifted its stake in Iradimed by 2,151.6% in the first quarter. Comerica Bank now owns 1,441 shares of the medical equipment provider’s stock worth $63,000 after purchasing an additional 1,377 shares during the last quarter. Huntington National Bank boosted its position in shares of Iradimed by 51.3% during the third quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock valued at $75,000 after buying an additional 504 shares during the period. Gladius Capital Management LP grew its stake in shares of Iradimed by 126.6% during the third quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider’s stock valued at $87,000 after buying an additional 965 shares during the last quarter. Finally, Quantbot Technologies LP raised its holdings in shares of Iradimed by 83.0% in the third quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider’s stock worth $117,000 after buying an additional 1,052 shares during the period. 92.34% of the stock is currently owned by institutional investors.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.